As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.
26 Analysts have issued a Axsome Therapeutics, Inc. forecast:
26 Analysts have issued a Axsome Therapeutics, Inc. forecast:
| Jun '25 |
+/-
%
|
||
| Revenue | 495 495 |
70%
70%
|
|
| Gross Profit | 453 453 |
72%
72%
|
|
| EBITDA | -225 -225 |
25%
25%
|
|
| EBIT (Operating Income) EBIT | -231 -231 |
24%
24%
|
|
| Net Profit | -247 -247 |
20%
20%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
| Head office | United States |
| CEO | Herriott Tabuteau |
| Employees | 683 |
| Founded | 2012 |
| Website | www.axsome.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


